
Clinical research activities include genetic, imaging, electrophysiological and biomarker studies, as well as phase I-III clinical trials (P. Van Damme, MD, PhD). Basic research activities include generation of small animal models, rodent models and stem cell models for ALS and FTLD, and use them to identify and validate molecular targets for the treatment of these diseases (W. Robberecht MD, PhD, P. Van Damme, MD, PhD, and L. Van Den Bosch, PhD).
Contact
Specialists
Current trials
TUDCA-ALS (TUDCA)
TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALS
Read morePreLude (Lithium carbonate)
Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.
Read moreLighthouse (Triumeq)
Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALS
Read moreiAdore (Oral edaravone)
Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stress
Read more